Search

Displaying results 5101 - 5110 of 6198 in total
  1. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  2. Drug

    CN-105

    go.drugbank.com/drugs/DB18345
    Investigational

    CN-105 is a neuroprotective pentapeptide with the sequence Acetyl-Valine-Serine-Arginine-Arginine-Arginine-NH2 (Ac-VSRRR- NH2).

  3. Drug

    Phosphonoacetic Acid

    go.drugbank.com/drugs/DB02823
    Experimental

    A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent. [PubChem]

  4. Drug

    Ninvosudil

    go.drugbank.com/drugs/DB08756
    Investigational

    Y-27632 is an inhibitor of Rho-associated protein kinase. It inhibits calcium sensitization to affect smooth muscle relaxation.

  5. Drug

    Daunorubicin

    go.drugbank.com/drugs/DB00694
    ApprovedInvestigational

    A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

  6. Drug

    GC012F

    go.drugbank.com/drugs/DB22406
    Investigational

    GC012F is under investigation in clinical trial NCT06419166 (An Exploratory Clinical Study of GC012F Injection for Refractory gMG).

  7. Drug

    Nordazepam

    go.drugbank.com/drugs/DB14028
    Investigational

    An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

  8. Drug

    OPC1

    go.drugbank.com/drugs/DB17944
    Experimental

    OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.[L47082]

  9. Drug

    NGN-101

    go.drugbank.com/drugs/DB18335
    Investigational

    NGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene

  10. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.